Technical Analysis for NYMX - Nymox Pharmaceutical Corporation

Grade Last Price % Change Price Change
grade D 1.86 -2.11% -0.04
NYMX closed down 2.11 percent on Monday, November 11, 2019, on approximately normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline. It ran into resistance at its 50 day moving average.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical NYMX trend table...

Date Alert Name Type % Chg
50 DMA Resistance Bearish 0.00%
Fell Below 200 DMA Bearish 0.00%
20 DMA Resistance Bearish -2.11%
Fell Below 50 DMA Bearish -2.11%
180 Bearish Setup Bearish Swing Setup -2.11%
Bullish Engulfing Bullish -2.62%
Crossed Above 200 DMA Bullish -2.62%
Crossed Above 50 DMA Bullish -2.62%
MACD Bearish Centerline Cross Bearish 3.33%
Narrow Range Bar Range Contraction 3.33%

Older signals for NYMX ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development, and commercialization of drugs and diagnostic products for the aging population in the United States, Canada, Europe, and other countries. It provides AlzheimAlert, a urinary test that helps physicians in the diagnosis of Alzheimer's disease; and NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. The company's products under development include NX-1207, which in Phase III clinical trials for the treatment of benign prostatic hyperplasia, as well as in human clinical trials to treat hepatocellular carcinoma and localized prostate cancer; and NXC-4720, an antibacterial agent for the treatment of E. coli O157:H7 bacterial contamination in hamburger meat and other food and drink products, and for the treatment of urinary tract and other bacterial infections in humans. Its products under development also comprise NXB-4221 for the treatment of chronic and persistent urinary tract infections; NXB-5886 for the treatment of streptococcal infection; and NXT-1021 for the treatment of staphylococcal infection. In addition, the company is involved in the research and development of drugs at various treatments for Alzheimer's disease and other indications; drugs for the treatment of Alzheimer's disease that targets spherons; and neural thread protein-based drugs, as well as developing various therapeutic products that are in the preclinical stage for oncology indications. It has license and collaboration agreement with Recordati Ireland Ltd. for the development and commercialization of NX-1207. The company was founded in 1989 and is headquartered in Saint Laurent, Canada.
Medicine Biopharmaceutical Food Medical Specialties Infection Alzheimer's Disease Therapeutic Products Tobacco Products Diagnostic Products Bacterial Infections Hepatocellular Carcinoma Bacterial Diseases Benign Prostatic Hyperplasia Treatment Of Alzheimer's Disease Pathogenic Bacteria Urinary Tract Infection Treatment Of Benign Prostatic Hyperplasia
Is NYMX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 2.75
52 Week Low 1.25
Average Volume 59,650
200-Day Moving Average 1.8731
50-Day Moving Average 1.9048
20-Day Moving Average 1.9205
10-Day Moving Average 1.912
Average True Range 0.1104
ADX 26.94
+DI 27.3551
-DI 20.7945
Chandelier Exit (Long, 3 ATRs ) 1.9488
Chandelier Exit (Short, 3 ATRs ) 2.0412
Upper Bollinger Band 2.1383
Lower Bollinger Band 1.7027
Percent B (%b) 0.36
BandWidth 22.681593
MACD Line -0.0079
MACD Signal Line 0.0076
MACD Histogram -0.0156
Fundamentals Value
Market Cap 97.4 Million
Num Shares 52.4 Million
EPS -0.23
Price-to-Earnings (P/E) Ratio -8.09
Price-to-Sales 1081.14
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.97
Resistance 3 (R3) 1.97 1.94 1.95
Resistance 2 (R2) 1.94 1.91 1.94 1.94
Resistance 1 (R1) 1.90 1.90 1.89 1.90 1.94
Pivot Point 1.87 1.87 1.86 1.87 1.87
Support 1 (S1) 1.83 1.84 1.81 1.82 1.78
Support 2 (S2) 1.80 1.83 1.80 1.78
Support 3 (S3) 1.76 1.80 1.77
Support 4 (S4) 1.75